All News
Filter News
Found 808,606 articles
-
Ultragenyx to Present at Upcoming June 2019 Investor Conferences
6/2/2019
Ultragenyx Pharmaceutical Inc. announced that it will present at the following upcoming investor conferences
-
Daiichi Sankyo Presents Preliminary Phase 1 Data for TROP2 Targeting ADC DS-1062 in Patients with Non-Small Cell Lung Cancer at 2019 ASCO Annual Meeting
6/2/2019
First-in-human results presented for DS-1062, an investigational TROP2 targeting ADC, in patients with advanced NSCLC where no standard treatment is available
-
SCIEX Celebrates 30th Anniversary of API III and Unveils Innovations at ASMS 2019
6/2/2019
New technology innovations mark the company’s next milestones, and build on its pioneering history
-
LYNPARZA® (olaparib) First-Line Maintenance Therapy Nearly Doubled the Time Without Disease Progression or Death in Phase 3 POLO Trial for Patients with Germline BRCA-Mutated Metastatic Pancreatic Cancer
6/2/2019
22% of Patients Receiving LYNPARZA Remained Progression-Free After Two Years vs. 10% on Placebo, Following Platinum-Based Chemotherapy
-
Pivotal Phase 3 ARTEMIS Trial Data Demonstrates Consistent Safety and Efficacy of AR101 in Children and Adolescents with Peanut Allergy
6/2/2019
Aimmune Therapeutics, Inc. presented topline results from the pivotal European Phase 3 ARTEMIS clinical trial, which it previously announced had met its primary endpoint, demonstrating the efficacy and safety of AR101 in peanut-allergic children and adolescents after six months of dose escalation and a three-month therapeutic dosing phase.
-
Talaris Therapeutics Presents Data Demonstrating Improved Quality of Life for Patients Treated with FCR001
6/2/2019
Talaris Therapeutics, Inc. is presenting new data from its Phase 2 trial of FCR001 in living donor kidney transplant recipients in a poster at the 2019 American Transplant Congress in Boston.
-
SOTIO’s DCVAC/LuCa Significantly Improves Survival in Patients with Stage IV Non-small Cell Lung Cancer
6/2/2019
SOTIO, a biotechnology company owned by the PPF Group, presented new statistically and clinically significant results from its Phase I/II clinical trial evaluating DCVAC/LuCa, an active cellular immunotherapy product, in patients with stage IV non-small cell lung cancer.
-
BioGENEius Challenge Announces 2019 BioGENEius Hall of Fame Awardee
6/2/2019
The Biotechnology Institute announced the winner of the BioGENEius Hall of Fame Award, who will be recognized next week at the 2019 BIO International Convention in Philadelphia.
-
Spectrum Pharmaceuticals Announces Integrated Results from Two Phase 3 ROLONTIS® (eflapegrastim) Trials Being Presented at the ASCO Annual Meeting
6/2/2019
Spectrum Pharmaceuticals, Inc. announced integrated analysis results from two Phase 3 clinical trials of ROLONTIS.
-
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the ASCO 2019 Annual Meeting
6/2/2019
Puma Biotechnology, Inc., a biopharmaceutical company, will present updated interim results from a Phase II clinical trial of Puma’s drug neratinib at the American Society of Clinical Oncology 2019 Annual Meeting in Chicago.
-
BerGenBio Presents New Preliminary Clinical and Biomarker Data Showing Durable Response & Median Survival Rates in Phase II Trial With Bemcentinib and KEYTRUDA in Pts With Advanced NSCLC at ASCO 2019
6/2/2019
Phase II trial evaluating bemcentinib in combination with KEYTRUDA in advanced NSCLC patients shows 12-month survival data surpassing historical benchmarks in second-line treatment with PD-1 inhibitor monotherapy
-
IMFINZI® (Durvalumab) is the Only Immunotherapy to Demonstrate Overall Survival at Three Years in Unresectable, Stage III Non-Small Cell Lung Cancer
6/2/2019
Data presented at ASCO 2019 showed 57% of patients alive at three years vs. 43.5% on placebo
-
Amgen Highlights The Versatility Of The BiTE® Immuno-Oncology Platform In Multiple Tumor Types At ASCO 2019
6/2/2019
Updated Phase 1 Data of Investigational AMG 420 in Relapsed and/or Refractory Multiple Myeloma Highlighted in Oral Presentation and Accepted for Best of ASCO®
-
Phase 3 COLUMBA Study Investigating a Subcutaneous Formulation of DARZALEX® (daratumumab) Showed Non-Inferiority to Intravenous Administration in Patients with Relapsed/Refractory Multiple Myeloma
6/2/2019
New formulation also showed shorter administration time and lower rate of infusion-related reactions
-
BRACAnalysis CDx® Companion Diagnostic Test Identifies Patients with Metastatic Pancreatic Cancer Who Benefited from Treatment with Lynparza® (olaparib)
6/2/2019
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine,today announced that its BRACAnalysis CDx® companion diagnostic test effectively identified patients with metastatic pancreatic cancer who benefitted from treatment with Lynparza® (olaparib) in the Phase III POLO study.
-
BioMarker Strategies to Present at the BIO 2019 International Convention in Philadelphia
6/2/2019
Demonstrations of the SnapPath® Cancer Diagnostics System Will Be Provided During Exhibit Hours
-
DARZALEX® (daratumumab) Investigational Study Shows Increased Depth of Response and Longer Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who are Eligible for a Transplant
6/2/2019
The Phase 3 CASSIOPEIA study is one of the largest transplant studies ever conducted in multiple myeloma, and the largest study conducted with DARZALEX
-
Celgene Presents Data from a Phase 1/2 Clinical Study of Iberdomide in Combination with Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma at ASCO 2019
6/2/2019
Investigational treatment demonstrates favorable early safety and efficacy data in patients who had received a median five prior treatments including immunomodulatory agents, proteasome inhibitors and anti-CD38 agents
-
Children's Hospital of Philadelphia Celebrates 23ʳᵈ Annual Fetal Surgery Family Reunion
6/2/2019
Yearly event gathers patients and families who were treated in the Center for Fetal Diagnosis and Treatment
-
Khiron Announces Completion of New Lab Facilities, With Initial Capacity of 3 Tonnes of Extract Per Year
6/2/2019
Khiron Life Sciences Corp. is pleased to announce the completion of construction and the initiation of operations in its cultivation, extraction, and analysis facilities in Ibague, Colombia, where significant progress has been made towards the commercial registration and production of medical cannabis products targeting 6 million potential patients across the country.